CBS 2019
CBSMD教育中心
中 文

ASCVD Prevention

Abstract

Recommended Article

Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study Nicotine promotes vascular calcification via intracellular Ca21-mediated, Nox5-induced oxidative stress, and extracellular vesicle release in vascular smooth muscle cells Non-obstructive High-Risk Plaques Increase the Risk of Future Culprit Lesions Comparable to Obstructive Plaques Without High-Risk Features: The ICONIC Study Clinical Risk Factors and Atherosclerotic Plaque Extent to Define Risk for Major Events in Patients Without Obstructive Coronary Artery Disease: The Long-Term Coronary Computed Tomography Angiography CONFIRM Registry Metabolic Interactions and Differences between Coronary Heart Disease and Diabetes Mellitus: A Pilot Study on Biomarker Determination and Pathogenesis Long-Term All-Cause and Cause-Specific Mortality in Asymptomatic Patients With CAC ≥1,000: Results From the CAC Consortium Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease

GuidelineJune 13, 2019

JOURNAL:JAMA Article Link

Primary Prevention of Sudden Cardiac Death

A D. Beaser; Adam S. Cifu, MD; Hemal M. Nayak. Keywords: rhythem dysorder; sudden cardiac death; primary prevention; LVEF; heart failure; ventricular fibrillation

ABSTRACT

Ventricular arrhythmias range from benign premature ventricular contractions to ventricular fibrillation and can be asymptomatic or have sudden cardiac death as the first manifestation. Sudden cardiac death is a major public health problem, accounting for 50% of all cardiovascular death.1 Although a plurality of sudden cardiac death occurs in the general population with no apparent cardiac risk factors, the risk is greatest in patients with LVEF of less than 30%, clinical heart failure, prior aborted cardiac arrest, or coronary artery disease.2